Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 4Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Venous Thromboembolism 1Thrombosis 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 180Cisplatin 157Radiotherapy 78Carboplatin 71Radiotherapy, Intensity-Modulated 69Cetuximab 66Magnetic Resonance Spectroscopy 64Nivolumab 63Paclitaxel 52Docetaxel 50Specimen Handling 45Radiation 35Gemcitabine 33Fluorouracil 31Surveys and Questionnaires 28Biopsy 27toripalimab 26Drug Therapy 26Platinum 25Surgical Procedures, Operative 24Standard of Care 231,2-diaminocyclohexaneplatinum II citrate 23cemiplimab 22atezolizumab 21Capecitabine 20Ipilimumab 19Chemoradiotherapy 19durvalumab 18Taxes 17Immune Checkpoint Inhibitors 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enoxaparin × Head & Neck × 1 year × Clear all
NCT07189897 2025-10-08

Apixaban or Enoxaparin After Head and Neck Cancer Surgery

State University of New York - Upstate Medical University

Phase 4 Recruiting
76 enrolled
Classical hematologyHead & Neck

Head and Neck Neoplasms, Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡